AstraZeneca sells two COPD drugs to a familiar partner as Pascal Soriot's oncology push marches on
As CEO Pascal Soriot continues his long-running pivot toward oncology, AstraZeneca is offloading another pair of respiratory drugs.
The drugmaker is selling off two medicines containing the active ingredient aclidinium bromide to Covis Pharma Group, the companies announced Monday morning, and receiving $270 million in return. Covis will also cover ongoing development costs for the drugs, which are marketed as Tudorza and Duaklir in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.